EGM
IONS icon

Engineers Gate Manager’s Ionis Pharmaceuticals IONS Stock Holding History

Engineers Gate Manager’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.18M Sell
14,840
-118,987
-89% -$8.95M 0.02% 991
2026
Q1 		$10M Buy
133,827
+111,636
+503% +$8.81M 0.13% 195
2025
Q4 		$1.76M Sell
22,191
-3,588
-14% -$270K 0.02% 756
2025
Q3 		$1.69M Sell
25,779
-7,339
-22% -$358K 0.02% 856
2025
Q2 		$1.31M Buy
+33,118
New +$1.08M 0.02% 975
2024
Q4 		– Sell
-78,874
Closed -$3.16M – 2401
2024
Q3 		$3.16M Buy
78,874
+62,554
+383% +$2.91M 0.06% 442
2024
Q2 		$778K Sell
16,320
-22,272
-58% -$913K 0.02% 1017
2024
Q1 		$1.67M Buy
38,592
+9,715
+34% +$463K 0.04% 554
2023
Q4 		$1.46M Buy
+28,877
New +$1.38M 0.04% 593
2023
Q3 		– Sell
-34,047
Closed -$1.4M – 1934
2023
Q2 		$1.4M Sell
34,047
-293
-0.9% -$11.3K 0.05% 510
2023
Q1 		$1.23M Buy
34,340
+14,363
+72% +$539K 0.05% 514
2022
Q4 		$755K Buy
19,977
+13,484
+208% +$567K 0.05% 644
2022
Q3 		$287K Sell
6,493
-10,210
-61% -$430K 0.02% 1137
2022
Q2 		$618K Buy
16,703
+6,835
+69% +$258K 0.02% 986
2022
Q1 		$366K Sell
9,868
-24,512
-71% -$802K 0.01% 1260
2021
Q4 		$1.05M Buy
34,380
+17,708
+106% +$557K 0.05% 605
2021
Q3 		$559K Buy
+16,672
New +$628K 0.03% 798
2021
Q2 		– Sell
-29,160
Closed -$1.31M – 1804
2021
Q1 		$1.31M Buy
29,160
+22,040
+310% +$1.23M 0.06% 459
2020
Q4 		$403K Sell
7,120
-7,137
-50% -$356K 0.02% 1109
2020
Q3 		$676K Buy
+14,257
New +$792K 0.03% 827
2020
Q2 		– Sell
-7,598
Closed -$359K – 1834
2020
Q1 		$359K Sell
7,598
-6,153
-45% -$343K 0.03% 946
2019
Q4 		$831K Buy
+13,751
New +$819K 0.04% 740
2019
Q2 		– Sell
-27,200
Closed -$2.21M – 1253
2019
Q1 		$2.21M Buy
+27,200
New +$1.75M 0.13% 231
2015
Q3 		– Sell
-9,801
Closed -$564K – 798
2015
Q2 		$564K Buy
9,801
+3,868
+65% +$246K 0.06% 587
2015
Q1 		$378K Buy
+5,933
New +$403K 0.05% 633

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Engineers Gate Manager's IONS Position: Q2 2026 in Review

Engineers Gate Manager reduced its Ionis Pharmaceuticals (IONS) stake by 89% in Q2 2026, selling an estimated $8.95M and leaving 14,840 shares worth $1.18M. The position accounts for 0.02% of the portfolio, ranked #991.

Engineers Gate Manager first reported a position in IONS in Q1 2015 and has held it in 25 quarters since. The position peaked at $10M in Q1 2026. 513 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Engineers Gate Manager held 14,840 shares of Ionis Pharmaceuticals worth $1.18M as of Q2 2026.
  • Engineers Gate Manager sold 118,987 Ionis Pharmaceuticals shares in Q2 2026, an estimated $8.95M.
  • Ionis Pharmaceuticals made up 0.02% of Engineers Gate Manager's portfolio in Q2 2026, its #991 holding.
  • Engineers Gate Manager first reported a position in Ionis Pharmaceuticals in Q1 2015 and has held it in 25 quarters since.
  • Engineers Gate Manager's Ionis Pharmaceuticals position peaked at $10M in Q1 2026.
  • 513 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.